Exhibit 10.1

Date:
February 22, 2016
 
 
To:
Regeneron Pharmaceuticals, Inc.
 
777 Old Saw Mill River Road
 
Tarrytown, NY 10591-6707
 
 
Attention:
Dominick Agron
 
VP and Treasurer
 
777 Old Saw Mill River Road
 
Tarrytown, NY 10591-6707
 
 
Facsimile:
(914) 847-1555
 
 
From:
Citibank, N.A.
 
390 Greenwich Street
 
New York, NY 10013
 
 
Re:
Second Amendment of the Warrant Transaction between Citibank, N.A. and Regeneron
 
Pharmaceuticals, Inc. (this “Amendment”)

--------------------------------------------------------------------------------

Dear Sir/Madam:

Citibank, N.A. (“Citi”) and Regeneron Pharmaceuticals, Inc. (“Issuer”) are
parties to a warrant transaction evidenced by the Master Terms and Conditions
for Base Warrants Issued by Regeneron Pharmaceuticals, Inc. dated as of October
18, 2011, supplemented by the written confirmation dated as of October 18, 2011
and amended by the Amendment dated as of May 13, 2014 (as so supplemented and
amended, the “Confirmation”). Terms used herein but are not otherwise defined
shall have meanings assigned to them in the Confirmation.

Upon the effectiveness of each daily amendment as set forth in Paragraph 1
below, all references in the Confirmation to the “Number of Warrants” will be
deemed to be to the Number of Warrants as amended hereby and all references in
the Confirmation to the “Transaction” will be deemed to be to the Transaction as
amended hereby.

1. Amendments. For each Unwind Date (as defined below), effective upon the
closeout of Dealer’s Hedge Positions on such Unwind Date, the Number of Warrants
for each Component of the Transaction shall be reduced by 1/80th of the Daily
Number of Warrants (as defined below) for such Unwind Date, with each such
Number of Warrants rounded up to the nearest whole number, except that the
Number of Warrants for the Component with the latest Expiration Date shall be
reduced by the aggregate number resulting from such rounding.

2. Amendment Payment. In consideration of the amendments to the Transaction,
Issuer agrees to pay to Dealer on each Payment Date (as defined below) an amount
in USD (the “Daily Amendment Payment”) equal to the product of the Daily Number
of Warrants for the related Unwind Date and the Amendment Payment Amount per
Warrant (each as defined below); provided that the sum of the Daily Amendment
Payments shall not exceed the Maximum Amendment Payment Amount (as defined
below); provided further, that in lieu of payment in USD, Issuer may elect in
its sole

    

--------------------------------------------------------------------------------

discretion to satisfy, with respect to any Unwind Date, the Daily Amendment
Payment in Shares as provided in Annex B hereto.

Daily Number of Warrants:
For any Unwind Date, a number of Warrants as determined by Dealer, in its
good-faith, commercially reasonable discretion, with respect to which Dealer has
closed out its Hedge Positions on such Unwind Date; provided that the sum of the
Daily Number of Warrants shall not exceed the Maximum Number of Warrants (as
defined below).

Maximum Number of Warrants:
975,142

Amendment Payment Amount
per Warrant:
As set forth in Annex A, to be the amount specified for the relevant Unwind Date
Price.

Maximum Amendment
Payment Amount:
USD 214,754,712.22 (in the aggregate); provided, however, that: (i) the Maximum
Amendment Payment Amount with respect to Unwind Dates where the Unwind Date
Price is greater than USD 350.00 shall be USD 64,754,712.22 (in the aggregate);
(ii) the Maximum Amendment Payment Amount with respect to Unwind Dates where the
Unwind Date Price is greater than USD 325.00 shall be USD 114,754,712.22 (in the
aggregate); and (iii) the Maximum Amendment Payment Amount with respect to
Unwind Dates where the Unwind Date Price is greater than USD 300.00 shall be USD
164,754,712.22 (in the aggregate).

Payment Date:
For each Unwind Date, the third Currency Business Day following such Unwind
Date.

Unwind Date:
Each Scheduled Trading Day during the Unwind Period on which Dealer has closed
out its Hedge Positions in respect of Warrants.

Unwind Period:
Each Exchange Business Day during the period commencing on February 22, 2016 and
ending on May 5, 2016 (inclusive).

Unwind Date Price:
For any Unwind Date, the volume-weighted average of the per Share prices at
which Dealer purchases Shares in order to close out its Hedge Positions in
respect of the Daily Number of Warrants on such Unwind Date; provided that
Dealer shall not effect any such purchases at a price per Share in excess of the
Limit Price.

Limit Price:
USD 375.00

3. Representations and Warranties.

(a)     Each party represents to the other party that:

(i)    It is duly organized and validly existing under the laws of the
jurisdiction of its organization or incorporation and, if relevant under such
laws, in good standing.

3

--------------------------------------------------------------------------------

(ii)    It has the power to execute this Amendment and any other documentation
relating to this Amendment to which it is a party, to deliver this Amendment and
any other documentation relating to this Amendment that it is required by this
Amendment to deliver and to perform its obligations under this Amendment and has
taken all necessary action to authorize such execution, delivery and
performance.

(iii)    Such execution, delivery and performance do not violate or conflict
with any law applicable to it, any provision of its constitutional documents,
any order or judgment of any court or other agency of government applicable to
it or any of its assets or any contractual restriction binding on or affecting
it or any of its assets.

(iv)    All governmental and other consents that are required to have been
obtained by it with respect to this Amendment have been obtained and are in full
force and effect and all conditions of any such consents have been complied
with.

(v)    Its obligations under this Amendment constitute its legal, valid and
binding obligations, enforceable in accordance with their respective terms
(subject to applicable bankruptcy, reorganization, insolvency, moratorium or
similar laws affecting creditors' rights generally and subject, as to
enforceability, to equitable principles of general application (regardless of
whether enforcement is sought in a proceeding in equity or at law)).

(b)     Issuer represents and warrants to and for the benefit of Dealer as
follows:

(i)    (A) On the date hereof, Issuer is not aware of any material non-public
information regarding Issuer or the Shares and (B) its most recent Annual Report
on Form 10-K, taken together with all reports and other documents subsequently
filed by Issuer with the Securities and Exchange Commission pursuant to the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), when
considered as a whole (with the more recent such reports and documents deemed to
amend inconsistent statements contained in any earlier such reports and
documents), does not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances in which they were made,
not misleading.

(ii)    On the date hereof and on each Payment Date, (A) the assets of Issuer at
their fair valuation exceed the liabilities of Issuer, including contingent
liabilities, (B) the capital of Issuer is adequate to conduct the business of
Issuer and (C) Issuer has the ability to pay its debts and obligations as such
debts mature and does not intend to, or does not believe that it will, incur
debt beyond its ability to pay as such debts mature.

(iii)    Issuer acknowledges its responsibilities under applicable
federal securities laws, including, without limitation, Rule 10b-5 under the
Exchange Act, in relation to the Transaction and its amendment.

(iv)    Issuer is entering into this Amendment in good faith and not as part of
a plan or scheme to evade the prohibitions of Rule 10b5-1 under the Exchange Act
(“Rule 10b5-1”) or any other antifraud or anti-manipulation provisions of the
federal or applicable state securities laws and that it has not entered into or
altered and will not enter into or alter any corresponding or hedging
transaction or position with respect to the Shares. Issuer acknowledges that it
is the intent of the parties that this Amendment comply with the requirements of
paragraphs (c)(1)(i)(A) and (B) of Rule 10b5-1 and this Amendment shall be
interpreted to comply with the requirements of Rule 10b5-1(c).

(v)    Issuer will not seek to control or influence Dealer’s decision to make
any “purchases or sales” (within the meaning of Rule 10b5-1(c)(1)(i)(B)(3)) of
Shares during the period beginning on the first Unwind Date and ending on the
last Unwind Date (such period, the “Unwind Period”), including, without
limitation, Dealer’s decision to enter into any hedging transactions. Issuer
represents and warrants that it has consulted with its own advisors as to the
legal aspects of its adoption and implementation of this Amendment under Rule
10b5-1.

(vi)    Issuer acknowledges and agrees that any amendment, modification, waiver
or termination of this Amendment must be effected in accordance with the
requirements for the amendment or termination of a “plan” as defined in Rule
10b5-1(c). Without limiting the generality of the foregoing, any such amendment,
modification, waiver or termination shall be made in good faith and not as part
of a plan or scheme to evade the prohibitions of Rule 10b5-1,

4

--------------------------------------------------------------------------------

and no such amendment, modification or waiver shall be made at any time at which
Issuer is aware of any material non-public information regarding Issuer or the
Shares.

(vii)    In the event Issuer elects to pay the Amendment Payment by delivering
Shares in accordance with Annex B hereto, the representation and agreement set
forth in Section 9.11 of the Equity Definitions shall be true and correct at the
time of such delivery, excluding any representations therein relating to
restrictions, obligations, limitations or requirements under applicable
securities laws.

4. Covenants of Issuer during Unwind Period. Issuer agrees with Dealer that
during the Unwind Period:

(a)     (i) the Shares or securities that are convertible into, or exchangeable
or exercisable for Shares, are not, and shall not be, subject to a “restricted
period,” as such term is defined in Regulation M and (ii) Issuer shall not
engage in any “distribution,” as such term is defined in Regulation M, from the
beginning of the Unwind Period until the second Exchange Business Day
immediately following the Unwind Period;

(b)    On any Unwind Date, neither Issuer nor any “affiliated purchaser” (as
defined in Rule 10b-18) shall directly or indirectly (including, without
limitation, by means of any cash-settled or other derivative instrument)
purchase, offer to purchase, place any bid or limit order that would effect a
purchase of, or commence any tender offer relating to, any Shares (or an
equivalent interest, including a unit of beneficial interest in a trust or
limited partnership or a depository share) or any security convertible into or
exchangeable or exercisable for Shares; provided that, for the avoidance of
doubt, (i) for purposes of this Section 4(b) “affiliated purchaser” shall not
include Sanofi or any of its directly or indirectly wholly owned subsidiaries;
and (ii) this Section 4(b) shall not preclude Issuer from receiving (or
retaining) any Shares in payment of the option exercise price or receiving (or
retaining) any Shares in respect of tax withholding or other similar tax
obligation in connection with the exercise, vesting or delivery of any awards
granted under Issuer’s equity incentive award plans; provided, further, that
nothing contained herein shall be deemed to prevent the exercise and settlement
of any convertible bond hedging transaction entered into by the Issuer in
connection with the issuance of its 1.875% Senior Convertible Notes due 2016;
and

(c)    it (A) will not make any public announcement (as defined in Rule 165(f)
under the Securities Act) of any Merger Transaction or potential Merger
Transaction unless such public announcement is made prior to the opening or
after the close of the regular trading session on the Exchange for the Shares;
and (B) shall promptly (but in any event prior to the next opening of the
regular trading session on the Exchange on the first Unwind Date following such
announcement) notify Dealer following any such announcement that such
announcement has been made.

5. Dealer Activities during Unwind Period.

(a)    Dealer agrees with Issuer that, in connection with the closeout of any
Hedge Positions pursuant to this Amendment on each Unwind Date, it shall use
commercially reasonable efforts to make all purchases of Shares in a manner that
would comply with the limitations set forth in clauses (b)(1), (b)(2), (b)(3),
(b)(4) and (c) of Rule 10b-18, as if such rule were applicable to such
purchases, taking into account any applicable Securities and Exchange Commission
no-action letters as appropriate and subject to any delays between the execution
and reporting of a trade of the Shares on the Exchange and other circumstances
beyond Dealer’s control.

(b)    Dealer and Issuer agree and acknowledge that any transactions with
respect to the Shares (including, without limitation, any hedging transactions)
entered into by Dealer on any Unwind Date are entered into for Dealer’s own
account and on its own behalf and not for the account of, or on behalf of,
Issuer.

6. No Additional Amendments or Waivers. Except as amended hereby, all the terms
of the Transaction and provisions in the Confirmation shall remain and continue
in full force and effect and are hereby confirmed in all respects.

7. Counterparts. This Amendment may be signed in any number of counterparts,
each of which shall be an original, with the same effect as if all of the
signatures thereto and hereto were upon the same instrument.

5

--------------------------------------------------------------------------------

8. Governing Law. The provisions of this Amendment shall be governed by the New
York law (without reference to choice of law doctrine).

6

--------------------------------------------------------------------------------

Please confirm that the foregoing correctly sets forth the terms of our
agreement by executing this Amendment and returning it in the manner indicated
in the attached cover letter.

Citibank, N.A.

By:
/s/ Herman Hirsch
 
 
 
Name:
Herman Hirsch
 
 
 
Title:
Authorized Representative
 
 
 

7

--------------------------------------------------------------------------------

Agreed and Accepted By:

REGENERON PHARMACEUTICALS, INC.

By:
/s/ Dominick Agron
 
 
 
Name:
Dominick Agron
 
 
 
Title:
VP & Treasurer
 
 
 

8

--------------------------------------------------------------------------------

ANNEX A

Unwind Date Price
Amendment Payment Amount per Warrant
$300.00
$201.52
$305.00
$206.38
$310.00
$211.24
$315.00
$216.13
$320.00
$221.02
$325.00
$225.91
$330.00
$230.80
$335.00
$235.71
$340.00
$240.63
$345.00
$245.54
$350.00
$250.46
$355.00
$255.38
$360.00
$260.32
$365.00
$265.25
$370.00
$270.19
$375.00
$275.13

For an Unwind Date Price falling between the amounts appearing in such column,
the Amendment Payment Amount per Warrant will be calculated by Dealer using
linear interpolation. If the Amendment Payment Amount per Warrant is otherwise
not determinable pursuant to the foregoing because the Unwind Date Price is less
than the lowest Unwind Date Price set forth above, the Amendment Payment Amount
per Warrant will be determined by Dealer by linear extrapolation based on the
two lowest Unwind Date Prices set forth above.

9

--------------------------------------------------------------------------------

ANNEX B
SHARE SETTLEMENT PROVISIONS
1.    Payment of any Daily Amendment Payment in Shares by Issuer shall be made
by delivery on the Payment Date of a number of Shares satisfying the conditions
set forth in paragraph 2 below (the “Registered Settlement Shares”), or a number
of Shares not satisfying such conditions (the “Unregistered Settlement Shares”),
in either case with a value equal to such Daily Amendment Payment, with such
Shares’ value determined by Dealer in good faith and in a commercially
reasonable manner (which value shall, in the case of Unregistered Settlement
Shares, take into account a commercially reasonable illiquidity discount).

2.    Issuer may only deliver Registered Settlement Shares pursuant to paragraph
1 above if:
(a)    a registration statement covering the public resale of the Registered
Settlement Shares by Dealer (the “Registration Statement”) shall have been filed
with the Securities and Exchange Commission under the Securities Act and been
declared or otherwise become effective on or prior to the date of delivery, and
no stop order shall be in effect with respect to the Registration Statement; a
printed prospectus relating to the Registered Settlement Shares (including any
prospectus supplement thereto, the “Prospectus”) shall have been delivered to
Dealer, in such quantities as Dealer shall reasonably have requested, on or
prior to the date of delivery;
(b)    the form and content of the Registration Statement and the Prospectus
(including, without limitation, any sections describing the plan of
distribution) shall be reasonably satisfactory to Dealer;
(c)    as of or prior to the date of delivery, Dealer and its agents shall have
been afforded a reasonable opportunity to conduct a due diligence investigation
with respect to Issuer customary in scope for underwritten offerings of equity
securities and the results of such investigation are satisfactory to Dealer, in
its good faith discretion; and
(d)    as of the date of delivery, an agreement (the “Underwriting Agreement”)
shall have been entered into with Dealer in connection with the public resale of
the Registered Settlement Shares by Dealer substantially similar to underwriting
agreements customary for underwritten offerings of equity securities of a
similar size by companies similar to Issuer, in form and substance reasonably
satisfactory to Dealer, which Underwriting Agreement shall include, without
limitation, provisions substantially similar to those contained in such
underwriting agreements for offerings of a similar size by companies similar to
Issuer relating, without limitation, to the indemnification of, and contribution
in connection with the liability of, Dealer and its affiliates and the provision
of customary opinions, accountants’ comfort letters and lawyers’ negative
assurance letters.
3.    If Issuer delivers Unregistered Settlement Shares pursuant to paragraph 1
above:
(a)    all Unregistered Settlement Shares shall be delivered to Dealer (or any
affiliate of Dealer designated by Dealer) pursuant to the exemption from the
registration requirements of the Securities Act provided by Section 4(a)(2)
thereof;
(b)    as of or prior to the date of delivery, Dealer and any potential
purchaser of any such Unregistered Settlement Shares from Dealer (or any
affiliate of Dealer designated by Dealer) identified by Dealer shall be afforded
a commercially reasonable opportunity to conduct a due diligence investigation
with respect to Issuer customary in scope for private placements of equity
securities of a similar size by companies similar to Issuer (including, without
limitation, the right to have made available to them for inspection all
financial and other records, pertinent corporate documents and other information
reasonably requested by them);

10

--------------------------------------------------------------------------------

(c)    as of the date of delivery, Issuer shall enter into an agreement (a
“Private Placement Agreement”) with Dealer (or any affiliate of Dealer
designated by Dealer) in connection with the private placement of such
Unregistered Settlement Shares by Issuer to Dealer (or any such affiliate) and
the private resale of such Unregistered Settlement Shares by Dealer (or any such
affiliate), substantially similar to private placement purchase agreements
customary for private placements of equity securities of a similar size by
companies similar to Issuer, in form and substance commercially reasonably
satisfactory to Dealer, which Private Placement Agreement shall include, without
limitation, provisions substantially similar to those contained in such private
placement purchase agreements for offerings of similar size by companies similar
to Issuer relating, without limitation, to the indemnification of, and
contribution in connection with the liability of, Dealer and its affiliates and
the provision of customary opinions, accountants’ comfort letters and lawyers’
negative assurance letters, and shall provide for the payment by Issuer of all
commercially reasonable fees and expenses in connection with such resale,
including all commercially reasonable fees and expenses of counsel for Dealer,
and shall contain representations, warranties, covenants and agreements of
Issuer reasonably necessary or advisable to establish and maintain the
availability of an exemption from the registration requirements of the
Securities Act for such resale; and
(d)    in connection with the private placement of such shares by Issuer to
Dealer (or any such affiliate) and the private resale of such shares by Dealer
(or any such affiliate), Issuer shall, if so requested by Dealer, prepare, in
cooperation with Dealer, a private placement memorandum in form and substance
reasonably satisfactory to Dealer and customary for private placements of equity
securities of similar size by companies similar to Issuer.
4.    Dealer, itself or through an affiliate (the “Selling Agent”) or any
underwriter(s), will sell, in a commercially reasonable manner and over a
commercially reasonable period, all, or such lesser portion as may be required
hereunder, of the Registered Settlement Shares or Unregistered Settlement Shares
and any Makewhole Shares (as defined below) (together, the “Settlement Shares”)
delivered by Issuer to Dealer pursuant to paragraph 5 below in a commercially
reasonable manner commencing on the date one Settlement Cycle following the
Termination Date (such date, the “Net Share Settlement Date” for purposes of Net
Share Settlement by Issuer) and continuing until the date on which the aggregate
Net Proceeds (as such term is defined below) of such sales, as determined by
Dealer in a commercially reasonable manner, is equal to the Amendment Payment
(such date, the “Final Resale Date”). If the proceeds of any sale(s) made by
Dealer, the Selling Agent or any underwriter(s), net of any commercially
reasonable fees and commissions (including, without limitation, commercially
reasonable underwriting or placement fees) customary for similar transactions of
a similar size under the circumstances at the time of the offering, together
with commercially reasonable carrying charges and expenses incurred in
connection with the offer and sale of the Shares (including, but without
limitation to, the covering of any over-allotment or short position (syndicate
or otherwise)) (the “Net Proceeds”) exceed the Amendment Payment, Dealer will
refund, in USD, such excess to Issuer on the date that is three (3) Currency
Business Days following the Final Resale Date, and, if any portion of the
Settlement Shares remains unsold, Dealer shall return to Issuer on that date
such unsold Shares.
5.    If the Calculation Agent determines that the Net Proceeds received from
the sale of the Registered Settlement Shares or Unregistered Settlement Shares
or any Makewhole Shares, if any, pursuant to this paragraph 5 are less than the
Amendment Payment (the amount in USD by which the Net Proceeds are less than the
Amendment Payment being the “Shortfall” and the date on which such determination
is made, the “Deficiency Determination Date”), Issuer shall on the Exchange
Business Day next succeeding the Deficiency Determination Date (the “Makewhole
Notice Date”) deliver to Dealer, through the Selling Agent, a notice of Issuer’s
election that Issuer shall either (i) pay an amount in cash equal to the
Shortfall on the day that is one (1) Currency Business Day after the Makewhole
Notice Date, or (ii) deliver additional Shares. If Issuer elects to deliver to
Dealer additional Shares, then Issuer shall deliver additional Shares in
compliance with the terms and conditions of paragraph 2 or paragraph 3 above, as
the case may be (the “Makewhole Shares”), on the first Clearance System Business
Day which is also an Exchange Business Day following the Makewhole Notice Date
in such number as the Calculation Agent commercially reasonably believes would
have a market value on that Exchange Business Day equal to the Shortfall. Such
Makewhole Shares shall be sold by Dealer in accordance with the provisions
above; provided that if the sum of the Net Proceeds from the sale of the
originally delivered Shares and the Net Proceeds from the sale of any Makewhole
Shares is less than the Amendment Payment then Issuer shall, at its election,
either make such cash payment or deliver to Dealer further Makewhole Shares
until such Shortfall has been reduced to zero.

11

--------------------------------------------------------------------------------

6.    Notwithstanding the foregoing, and without limiting the Issuer’s ability
to elect to settle any Daily Amendment Payment in Shares, as provided in this
Annex B, in no event shall the aggregate number of Settlement Shares and
Makewhole Shares required to be delivered by the Issuer upon settlement of all
Daily Amendment Payments so settled in Shares, in the aggregate, be greater than
250,000 Shares (the “Maximum Number of Shares”). For the avoidance of doubt, in
no event will the Company be required to deliver cash in the event the aggregate
number of Settlement Shares and Makewhole Shares required to be delivered by the
Issuer upon settlement of all Daily Amendment Payments so settled in Shares, in
the aggregate, would, but for the foregoing sentence, exceed the Maximum Number
of Shares.

12